SCHEDULE 13G/A: BlackRock Maintains Significant Passive Stake in Tarsus Pharmaceuticals, Inc.

BlackRock, Inc. has filed an updated Schedule 13G, disclosing a 7.4% beneficial ownership stake in Tarsus Pharmaceuticals, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 3,092,735 shares of Tarsus Pharmaceuticals, Inc. common stock.
• This ownership represents 7.4% of the total outstanding common stock of Tarsus Pharmaceuticals, Inc.
• BlackRock holds sole voting power over 3,053,218 shares and sole dispositive power over 3,092,735 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual, routine regulatory filing about beneficial ownership and does not contain information that would significantly alter the sentiment towards the company or the reporting entity.

Positives

• BlackRock, Inc., a major institutional investor, maintains a significant passive stake of 7.4% in Tarsus Pharmaceuticals, Inc.

Negatives

• No negative information regarding Tarsus Pharmaceuticals, Inc. is disclosed in this beneficial ownership filing.

Risks

• The document does not detail specific risks related to Tarsus Pharmaceuticals, Inc.'s operations or financial health.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Tarsus Pharmaceuticals, Inc.'s future performance or strategic direction.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11." (Statement by Spencer Fleming, Managing Director of BlackRock, Inc.)

Industry Context

This filing is a routine disclosure by a large asset manager, BlackRock, indicating its passive investment stake in Tarsus Pharmaceuticals, Inc. It does not provide specific industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake in the company.

Next Steps

• No specific future actions, events, or milestones for Tarsus Pharmaceuticals, Inc. are mentioned in this filing.

Key Dates

Keywords

Tarsus Pharmaceuticals, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment